- Home
- ENLV vs EIC Comparison
ENLV vs EIC Comparison
Compare ENLV & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLV | EIC |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 228.8M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ENLV | EIC |
|---|---|---|
| Price | $0.67 | $10.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $20.00 | $12.63 |
| AVG Volume (30 Days) | ★ 409.3K | 77.2K |
| Earning Date | 05-29-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $9.17 |
| 52 Week High | $2.10 | $13.92 |
Technical Indicators
Market Signals| Indicator | ENLV | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 37.12 |
| Support Level | $0.66 | $9.78 |
| Resistance Level | $1.23 | $11.34 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 6.44 | 3.57 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.